A Phase 4 interventional study of i.v. iron sucrose and Oral iron in Colorectal Neoplasm and Iron Deficiency Anemia, sponsored by J. Uriach and Company. Status unknown at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-09-20.
Sponsored by J. Uriach and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 461 studies in Colorectal Neoplasms with a site in Spain — 96 open to participants now, 149 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.
Among the 461 studies in Colorectal Neoplasms with a site in Spain, this one is the 220th largest by enrollment of the 404 interventional ones that give a count, is one of 7 in phase 4, and was the 18th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →96 of the 461 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Blueprint Medicines Corporation · Sites in Spain, United States
Ages 18+
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 18–75
AbbVie · Sites in Spain, United States, Belgium and 7 more countries
Ages 18+
Gilead Sciences · Sites in Spain, United States, Australia and 1 more country
Ages 18+
Fundacion Clinic per a la Recerca Biomédica · Sites in Spain
Ages 50–69
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
461 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 146 · Phase 2 191 · Phase 3 73 · Phase 4 7
First in 1993; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 168 across the 404 interventional studies, 408 across the 54 observational. Of the 281 that completed or were terminated, 125 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
299 of 461 have an industry lead sponsor. The 10 most frequent:
J. Uriach and Company is the lead sponsor of 9 studies on the registry; none are open to participants now.
J. Uriach and Company has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
41 of the studies in Colorectal Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT05988645MiWEndo Solutions S.L.Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II) | 2026-11-29 |
| NCT05789069HiFiBiO TherapeuticsA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
Add all 41 to your calendar (.ics) → With an account.
Among the 461 studies in Colorectal Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the efficacy of intravenous iron sucrose in increasing preoperative haemoglobin values in patients with colo-rectal neoplasm and iron deficiency anemia, compared to the standard treatment with oral iron. It will also determine whether intravenous iron sucrose administration improves outcomes such as postoperative haemoglobin values, serum ferritin values, transfusional needs, postoperative complications, or length of hospital stay.
Most patients with colorectal neoplasm have iron deficiency, which can be triggered in the pre-operative period by a decrease of iron intake and the bleeding in the site of neoplasm.
In the postoperative period, iron deficiency can be aggravated by surgical bleeding.
Iron plays a leading rol in haemoglobin production, cell mitosis and immune system. Animal experimentation has shown that induced iron deficiency and mild anemia lead to postoperative mortality and lactacidemia in a model of peritonitis.
Moreover, anemia is the main risk factor to require intra and postoperative blood transfusions, and iron deficiency and anemia are associated to a larger number of postoperative complications (infections and longer hospital stay).
Oral iron therapy is the standard treatment in patients with preoperative iron deficiency, but iron levels inside red cells may not reach normality in time before surgery, and it can not be resumed until the patient can start again oral feeding.
In these patients, any increase in preoperative haemoglobin decreases the risk to need a blood transfusion during or after surgery.
This trial will compare standard oral iron and intravenous iron.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Preoperative variations in hemoglobin.
Postoperative variations in hemoglobin.
Blood transfusion needs (pre, intra and postoperative)
Postoperative complications:
- Pulmonary thromboembolism
- Infections
- Reintervention
- Death
Length of hospital stay
This study is status unknown, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron
J. Uriach and Company